The lab: Zwart group
Lab's research themes:
Our research is focused on epigenetic regulation in hormone-driven cancers. We integrate clinical trials with functional genomics and endocrinology, to identify mechanisms of therapy resistance and reveal novel therapeutic possibilities for companion diagnostics.
Hormonal therapies represent the first and most successful targeted therapies in cancer. In most breast and prostate cancers, hormonal therapy forms the very backbone of systemic treatment. However, resistance to therapy is common, and many patients relapse despite treatment. Our group studies hormonal action in multiple tumor types: endometrial cancer, lung cancer, breast cancer and prostate cancer. Our ultimate goal is to better understand hormonal signaling and elucidate therapy resistance in cancer, contributing to more personalized treatments, the identification of novel therapeutic options and minimizing over-treatment.
Merits of the lab:
As our lab philosophy, we bridge clinic and basic research, to accelerate clinical translation and ensure clinical validity of our findings. As main focus area, we study hormone action in cancer, in relation to the 3D genome and epigenetic mechanisms that dictate hormone action. We developed and refined innovative genomics technologies that enable us to chart the genome-wide action of transcription factors in small amounts of tumor tissue, and pioneered in implementing these technologies in (neoadjuvant) clinical trials.
As an intrinsic component of our lab strategy, we heavily invested in computational biology, functional genetic screens and drug repurposing strategies, creating a full-circle scientific environment geared to foster new exciting and clinically-relevant discoveries. For further background, see the lab’s website or https://pubmed.ncbi.nlm.nih.gov/?term=zwart+w&filter=years.2003-2022.
Why do we want medical doctors?
We have a highly diverse and international team, housing biologists, computational scientists, molecular endocrinologists as well as clinicians. Our team is very closely connected to clinical research labs within the institute as well as (inter)nationally, providing the best possible training environment for clinician-researchers.
The position
What’s the main purpose of our research?
We study hormone action in multiple tumor types; breast cancer, prostate cancer, endometrial cancer and lung cancer. Our ultimate goal is to better understand hormonal signaling and elucidate therapy resistance in cancer, contributing to personalized clinical decision-making, optimized treatment selection, identification of novel therapeutic options and minimized over-treatment. Hormone receptors are under tight epigenetic control and impacted by the genetic context in which the tumor develops and progresses. By untangling this complex (epi)genetic interplay of hormone receptor biology with its environment in situ, and understanding how this is impacted by treatment, we aim to directly contribute to fully tailored endocrine treatment selection in the future, selecting the most suitable therapy for the individual patient.
How we will do it?
We design our research as a full-circle strategy; starting from clinical observation, towards functional genomics and mechanistic studies in advanced model systems, and back again to the clinic. This involves clinical sample handing, molecular pathology, wet-lab and dry-lab genomics analyses, drug screens and ultimately the design of new clinical trials.
Why is this important?
Resistance to therapy is quite common in cancer patients while it is the very backbone of current systemic treatment for many cancer such as prostate, breast and lung cancer. Therefore, it is important to better understand the development of resistance and explore new therapeutic options. By embedding our research within ongoing and future clinical trials, we directly contribute to finding a solution to this urgent clinical problem.
Who is a good fit for the project?
The ideal candidate has both wet-lab and dry-lab research experience. Most importantly, the candidate should have a keen drive to learn new techniques and proactively engage with other research disciplines.
Other positions
IDIBAPS#4 – Mechanisms involved in strenuous exercise-induced atrial myocardial fibrosis
IC#4 – The role polyglutamylation in tauopathic neurodegeneration
IC#3 – Evaluation of the efficiency of immunotherapy by tracing ctDNA in metastatic NSCLC and triple-negative breast cancer patients
IC#2 – New targetable vulnerabilities for the treatment of chemoresistant breast and ovarian BRCA1/2-mutated tumors
IDIBAPS#3 – Mechanisms involved in vascular inflammation/remodeling in systemic vasculitis
IDIBAPS#2 – Mechanisms and therapies for Myeloma, amyloidosis, macroglobulinemia and other gammapathies
IDIBAPS#1 – Developing and investigating computing, machine learning and physiological modelling for understanding each individual heart towards personalised medicine
BRIC#6 – Tumour evolution, heterogeneity, and understanding of the mutational processes leading to aggressive disease
IC#1 – The role of RNASE1 in lung metastatic niche establishment by breast cancer cells
MDC#3 – Neuromuscular and Cardiovascular Cell Biology
MDC#2 – Molecular and cellular basis of behavior
MDC#1 – Host-microbiome factors in cardiovascular disease
NKI#1 – Epigenetic regulation in hormone-driven cancers and therapy resistance
VIB#8 – Mechanisms of inflammation and associated tissue damage in musculoskeletal diseases
VIB#7 – Endothelial immunosuppressive mystery genes for alternative immunotherapy: artificial intelligence-driven target discovery and validation
VIB#6 – Cellular metabolism and metabolic regulation in cancer metastasis
VIB#5 – Unraveling the molecular mechanisms of neuronal degeneration in motor neuron diseases
VIB#4 – Identification of universal biomarkers of metastatic melanoma in CTCs
VIB#3 – Basic mechanisms of Alzheimer’s disease and neurodegeneration
VIB#2 – Integrative genomics to underpinning somatic evolution, tumour heterogeneity, and treatment resistance
VIB#1 – Medical biotechnology to improve hepatocellular carcinoma diagnostics
BRIC#5 – The impact of severe maternal respiratory tract infections on fetal brain development and offspring behavior
